Skip to content

    Neuland Labs.

    NEULANDLABMixed
    Healthcare·31 Jul 2025
    Management Summary

    Neuland Labs reported a challenging Q1 FY26, with a significant 32.4% YoY revenue decline due to the lumpy nature of order flows in its CMS and GDS segments. This top-line weakness led to severe operating deleverage, causing a sharp fall in profitability. Despite the poor start, management maintained its full-year growth outlook, banking on the commercialization of a new CMS molecule and the ramp-up of its new Unit 3 production block in the latter half of FY26. The focus remains on strategic investments in peptides and capacity expansion to drive future growth.

    Highlights

    8

    • Total Income was ₹300.6 crores, a sharp decrease of 32.4% YoY from ₹444 crores in Q1FY25.

    • EBITDA stood at ₹42.1 crores with an EBITDA margin of 14.4%, significantly impacted by operating deleverage.

    • Profit After Tax (PAT) declined to ₹13.7 crores, compared to ₹98.3 crores in the same period last year.

    • Quarterly EPS was ₹10.7 per share.

    • Gross Margin remained relatively stable at 55.3% compared to 56.1% in Q1FY25.

    • The CMS (Custom Manufacturing Solutions) business contributed approximately 44% to the quarter's revenue.

    • Free Cash Flow was negative at -₹66 crores for the quarter, impacted by higher inventory.

    • Management reiterated confidence in achieving FY26 growth objectives despite the weak start, expecting a stronger second half.

    Concerns

    2

    • Quarterly Revenue Volatility (Lumpiness)

    • Operating Deleveraging

    What Changed3

    vs Q2 FY26

    Tone shiftGood → MixedGuidance items4 → 6 (+2)Risks discussed3 → 4 (+1)

    Key financials

    Single quarter

    07 metrics
    1. 01Total Income₹300.6 Cr-32.4%YoY
    2. 02EBITDA₹42.1 Cr
    3. 03EBITDA Margin14.4%
    4. 04Gross Margin55.3%
    5. 05PAT₹13.7 Cr-86.1%YoY

    Segment breakdown

    CMS (Custom Manufacturing Solutions)
    44% Revenue Contribution
    List

    Guidance & targets

    6
    CategoryTargetPriority
    Capex
    Total Capex
    around Rs.250 crores
    		High
    Growth
    Long-term Revenue CAGR
    20%
    		Medium
    Growth
    FY26 Revenue Growth
    Strong growth
    		Low
    Pipeline
    New Molecule Commercialization
    1 new molecule
    		High
    Capacity
    Peptide Facility Completion
    Completion of new facility
    		Medium
    Margin
    Margin Recovery
    Recovery from suppressed levels
    		Low

    Risks & concerns

    5
    RiskSeverity

    Quarterly Revenue Volatility (Lumpiness)

    Management repeatedly stressed that the business is inherently uneven quarter-on-quarter due to order flows in CMS and specialty GDS, making short-term analysis difficult. — Management acknowledged

    high

    Operating Deleveraging

    The sharp drop in Q1 revenue directly led to margin compression. Margin recovery is highly dependent on achieving revenue growth in subsequent quarters. — Management acknowledged

    high

    Working Capital Strain

    Working capital deteriorated to 145 days of sales due to higher inventory, resulting in negative free cash flow of ₹66 crores. — Management acknowledged

    medium

    CMS Business Concentration

    With CMS contributing 44% of revenue and being a high-margin but lumpy business, its performance disproportionately impacts overall results. — Analyst acknowledged

    medium

    Areas of Evasion(1)

    • Specific quantitative growth target for FY26

    Q&A highlights

    3

    “Strong growth is the word that we are leaving you with. So please forgive us for not being more specific than that.”

    Management refused to quantify its 'strong growth' outlook for the current fiscal year, creating uncertainty for near-term forecasts despite expressing confidence.

    asked by Neel Shah

    2 min read5 chapters

    Detailed Narrative

    01

    Q1 FY26 Performance: A Story of Deleveraging

    Neuland Labs reported a significantly weak start to the fiscal year, with total income falling 32.4% YoY to ₹300.6 crores. Management attributed this to the inherent lumpiness of its business, particularly in commercial CMS projects and the GDS Prime segment. This revenue decline led to severe operating deleveraging, with EBITDA margins contracting to 14.4%. Consequently, Profit After Tax (PAT) saw a steep decline to ₹13.7 crores from ₹98.3 crores in Q1FY25.

    02

    Full-Year Outlook Hinges on H2 Recovery

    Despite the poor Q1 performance, management reiterated its confidence in resuming the growth trajectory for the full year FY26, using FY24 as the base. They guided for 'strong growth' but refrained from giving a specific number. The expected recovery is back-ended, contingent on the commercialization of a new CMS molecule during the year and the ramp-up of the newly capitalized production block at Unit 3, which is expected to start commercial production later in the fiscal year.

    03

    Strategic Focus on Peptides and Capacity Expansion

    The company's investment in the high-growth peptide segment remains on track, with the new dedicated facility expected to be completed in the next financial year. Management emphasized their 15+ years of experience as a key competitive advantage. In parallel, Neuland is pursuing a capex of ₹250 crores in FY26, with 60% allocated to growth. This includes expanding Unit 1 by acquiring adjacent land, a strategy to add FDA-approved capacity more quickly than a greenfield project.

    04

    CMS and GDS Segment Dynamics

    The Custom Manufacturing Solutions (CMS) business was the primary revenue driver, contributing ~44% of the total. Management expects continued buoyancy in this segment. The GDS (Generic Drug Substances) business was subdued. The Speciality GDS segment's performance was impacted by the reclassification of Ezetimibe to the Prime GDS segment and the phasing of dispatches for other products. Management, however, does not see any concerns for the full-year performance of the Speciality portfolio.

    05

    Working Capital and Cash Flow Pressures

    The uneven order flow impacted the balance sheet, with working capital increasing to 145 days of sales due to a build-up in inventory. This resulted in a negative free cash flow of ₹66 crores for the quarter. While the company maintains a negative net debt position of ₹165 crores, the management of working capital will be a key priority going forward⏳.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.